The NK-1 Receptor Antagonist Aprepitant As a Broad Spectrum Antitumor Drug

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2009 Jan 17

PMID 19148578

Citations 62

Authors

Miguel Munoz

Marisa Rosso

Affiliations

Soon will be listed here.

Abstract

Aprepitant is a selective high-affinity antagonist of human substance P (SP)/Neurokinin-1 (NK-1) receptors. Until now this drug has been used as anxiolytic, antidepressant and antiemetic. It has been demonstrated that SP induces cell proliferation and NK-1 receptor antagonists different to aprepitant inhibit growth in several human cancer cell lines, where NK-1 receptors are overexpressed. The purpose of this study is to demonstrate the antitumor action of aprepitant. We performed an in vitro study of the growth inhibition capacity of the NK-1 receptor antagonist aprepitant against glioma, neuroblastoma, retinoblastoma and pancreas, larynx, gastric and colon carcinomas cell lines. Coulter counter was used to determine viable cell numbers followed by application of the MTS colorimetric method. Furthermore, a DAPI method was applied to demonstrate apoptosis. We have demonstrated: aprepitant at (5-70 microM) concentration elicits growth cell inhibition in a concentration dependent manner in all tumor cell line studied. Maximum inhibition (100%) was observed when the aprepitant was administered at a concentration of > or = 70 microM in all tumor cell lines studied. The specific antitumor action of aprepitant occurs through the NK-1 receptor and tumor cells death was by apoptosis pathway. These findings reported here for the first time indicate that aprepitant is a new and promising broad spectrum antitumor drug in the treatment of cancer.

Citing Articles

Identifying the potential mediators of pathological complete response to neoadjuvant chemotherapy among TACR1 gene polymorphisms: a study on breast cancer patients.

Ghorbani M, Namazi S, Dehghani M, Razi F, Khalvati B, Dehshahri A Breast Cancer Res Treat. 2025; .

PMID: 40080356 DOI: 10.1007/s10549-025-07674-x.

Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Munoz M, Rosso M Cancers (Basel). 2025; 17(3).

PMID: 39941886 PMC: 11816061. DOI: 10.3390/cancers17030520.

Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland.

Alcaide C, Perez F, Esteban F, Munoz M Pituitary. 2024; 28(1):5.

PMID: 39724307 DOI: 10.1007/s11102-024-01490-0.

Neuronal substance P drives metastasis through an extracellular RNA-TLR7 axis.

Padmanaban V, Keller I, Seltzer E, Ostendorf B, Kerner Z, Tavazoie S Nature. 2024; 633(8028):207-215.

PMID: 39112700 PMC: 11633843. DOI: 10.1038/s41586-024-07767-5.

Substance P - a regulatory peptide with defense and repair functions. Results and perspectives for the fight against COVID-19.

Mehboob R, Oehme P, Anwar T, von Kries J Front Neurol. 2024; 15:1370454.

PMID: 38872816 PMC: 11169637. DOI: 10.3389/fneur.2024.1370454.

References

Hokfelt T, PERNOW B, Wahren J . Substance P: a pioneer amongst neuropeptides. J Intern Med. 2001; 249(1):27-40. DOI: 10.1046/j.0954-6820.2000.00773.x. View

Rosso M, Robles-Frias M, Covenas R, Salinas-Martin M, Munoz M . The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol. 2008; 29(4):245-54. DOI: 10.1159/000152942. View

Varty G, Cohen-Williams M, Hunter J . The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol. 2003; 14(1):87-95. DOI: 10.1097/00008877-200302000-00009. View

Yu J, Cadet J, Angulo J . Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain. J Neurochem. 2002; 83(3):613-22. DOI: 10.1046/j.1471-4159.2002.01155.x. View

Munoz M, Rosso M, Aguilar F, Gonzalez-Moles M, Redondo M, Esteban F . NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs. 2007; 26(2):111-8. DOI: 10.1007/s10637-007-9087-y. View

Bang R, Sass G, Kiemer A, Vollmar A, Neuhuber W, Tiegs G . Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J Pharmacol Exp Ther. 2003; 305(1):31-9. DOI: 10.1124/jpet.102.043539. View

Friess H, Zhu Z, Liard V, Shi X, Shrikhande S, Wang L . Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest. 2003; 83(5):731-42. DOI: 10.1097/01.lab.0000067499.57309.f6. View

Kramer M, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek J . Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998; 281(5383):1640-5. DOI: 10.1126/science.281.5383.1640. View

Luo W, Sharif T, Sharif M . Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res. 1996; 56(21):4983-91. View

10.

Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C . Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci. 2005; 46(7):2567-70. DOI: 10.1167/iovs.04-1530. View

11.

Esteban F, Munoz M, Gonzalez-Moles M, Rosso M . A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 2006; 25(1):137-45. DOI: 10.1007/s10555-006-8161-9. View

12.

Lang K, Drell 4th T, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker K . Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer. 2004; 112(2):231-8. DOI: 10.1002/ijc.20410. View

13.

Reeve J, Bleehen N . [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophys Res Commun. 1994; 199(3):1313-9. DOI: 10.1006/bbrc.1994.1374. View

14.

Rupniak N, Carlson E, Boyce S, Webb J, Hill R . Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain. 1996; 67(1):189-195. DOI: 10.1016/0304-3959(96)03109-0. View

15.

Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi C . Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990; 40(2):264-78. DOI: 10.1016/0026-2862(90)90024-l. View

16.

Varty G, Cohen-Williams M, Morgan C, Pylak U, Duffy R, Lachowicz J . The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology. 2002; 27(3):371-9. DOI: 10.1016/S0893-133X(02)00313-5. View

17.

Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi C, Manzini S . Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer. 2000; 82(2):480-7. PMC: 2363296. DOI: 10.1054/bjoc.1999.0946. View

18.

Munoz M, Perez A, Rosso M, Zamarriego C, Rosso R . Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res. 2004; 14(3):183-8. DOI: 10.1097/01.cmr.0000129376.22141.a3. View

19.

Bigioni M, Benzo A, Irrissuto C, Maggi C, Goso C . Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs. 2005; 16(10):1083-9. DOI: 10.1097/00001813-200511000-00007. View

20.

Guha S, Eibl G, Kisfalvi K, Fan R, Burdick M, Reber H . Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 2005; 65(7):2738-45. DOI: 10.1158/0008-5472.CAN-04-3197. View